Regenerative Medical Solutions
Business hours
| Monday | 9:00am to 5:00pm |
| Tuesday | 9:00am to 5:00pm |
| Wednesday | 9:00am to 5:00pm |
| Thursday | 9:00am to 5:00pm |
| Friday | 9:00am to 5:00pm |
| Saturday | - |
| Sunday | - |
About us
Regenerative Medical Solutions (RMS) is a biotechnology company focused on transforming diabetes treatment through innovative stem cell technology. Based in Madison, WI, RMS specializes in developing stem cell-derived Islet-Like Clusters (ILCs) for both continued research purposes and therapeutic applications. Our proprietary technology, developed over 15 years of research, enables scalable production of ILCs that function like human pancreatic islet cells, offering new hope for diabetes treatment. RMS is dedicated to advancing diabetes care through cutting-edge research, product development, and clinical solutions.
Innovative ILC Cell Research for Diabetes
| Year established | 2012 |
| Associations | University of Wisconsin-Madison: Collaborates with stem cell pioneer Dr. James Thomson, Northwestern University: Advisor Harry M. Jansen Kraemer, Jr., is a Clinical Professor, University of California, San Francisco (UCSF): Advisor Dr. Peter G. Stock |
| Tags | Regenerative Medicine, Stem Cell Therapy, Diabetes Treatment, Islet-Like Cluster Cells, Pancreatic Beta Cells, Cellular Therapeutics for Diabetes, Stem Cell Research, iPSC Differentiation, Biotechnology for Diabetes, Islet-Like Clusters Cell Kits, Regenerative Medicine with Stem Cells for Diabetes, Diabetes Stem Cell Treatment and Research, Biotechnology Research Organization for Diabetes Therapeutics |
| Specialties | Stem Cell Research – Focused on the differentiation of pluripotent stem cells into pancreatic islet, Diabetes Treatment Innovation – Developing novel therapies to restore insulin production in patients, Cellular Therapeutics – Pre-clinical development of autologous and allogeneic stem cell therapies., Pancreatic Islet Biology – Specializing in creating islet-like clusters that mimic human pancreatic, iPSC Technology – Utilizing induced pluripotent stem cells (iPSCs) for diabetes research and treatme, Drug Discovery Tools – Providing reliable, scalable ILC cells for research and testing., Toxicity Screening – Using ILC cells to screen for toxicity and efficacy in drug development. |
| Products | ILC Cell Technology – Human iPSC-derived Islet-Like Clusters (ILCs) for research., ILC Cellular Therapeutics – Stem cell-based therapeutic candidates in pre-clinical development., ILC Cells Kit – Cryopreserved single-cell ILCs for diabetes research, discovery, and toxicity tests., Allogeneic ILC Cellular Therapeutics – Stem cell therapy using donor-derived iPSCs to treat diabetes |
| Services | Diabetes Research Tools – Offering ILC cells for in vitro studies, drug research, and toxicity tests, Cell Therapy Development – Advancing autologous and allogeneic stem cell therapies for diabetes, Stem Cell Differentiation – Developing proprietary methods to create pancreatic islet-like cells, Clinical Trial Preparation – Pre-clinical development for cellular therapeutics targeting diabetes. |
| Video | https://www.youtube.com/watch?v=SG-CY0rN3sY |